The University of Chicago Header Logo

Connection

George Bakris to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications George Bakris has written about Drug Therapy, Combination.
George Bakris
Connection Strength
5.719
Drug Therapy, Combination
  1. Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1309-1318.
    View in: PubMed
    Score: 0.523
  2. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52.
    View in: PubMed
    Score: 0.266
  3. Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. Am J Med. 2021 10; 134(10):1195-1198.
    View in: PubMed
    Score: 0.169
  4. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702.
    View in: PubMed
    Score: 0.134
  5. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55.
    View in: PubMed
    Score: 0.124
  6. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? Curr Diab Rep. 2016 Apr; 16(4):24.
    View in: PubMed
    Score: 0.117
  7. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet. 2016 Jul 30; 388(10043):530-2.
    View in: PubMed
    Score: 0.116
  8. Summary and Conclusions. High Blood Press Cardiovasc Prev. 2015 Jul; 22 Suppl 1:S23.
    View in: PubMed
    Score: 0.111
  9. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015 Apr; 9(4):266-74.
    View in: PubMed
    Score: 0.108
  10. Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich). 2014 Feb; 16(2):141-8.
    View in: PubMed
    Score: 0.101
  11. Review of blood pressure control rates and outcomes. J Am Soc Hypertens. 2014 Feb; 8(2):127-41.
    View in: PubMed
    Score: 0.100
  12. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9.
    View in: PubMed
    Score: 0.095
  13. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100.
    View in: PubMed
    Score: 0.092
  14. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10.
    View in: PubMed
    Score: 0.091
  15. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
    View in: PubMed
    Score: 0.086
  16. Initial combination antihypertensives: let's ACCELERATE. Lancet. 2011 Jan 22; 377(9762):278-9.
    View in: PubMed
    Score: 0.082
  17. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010 Nov; 28(4):609-22.
    View in: PubMed
    Score: 0.081
  18. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10.
    View in: PubMed
    Score: 0.080
  19. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):450-5.
    View in: PubMed
    Score: 0.080
  20. Dual RAAS blockade is desirable in kidney disease: con. Kidney Int. 2010 Sep; 78(6):546-9.
    View in: PubMed
    Score: 0.079
  21. More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. J Hypertens. 2010 Jul; 28(7):1382-3.
    View in: PubMed
    Score: 0.079
  22. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
    View in: PubMed
    Score: 0.074
  23. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91.
    View in: PubMed
    Score: 0.074
  24. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med. 2009 Mar; 121(2):77-88.
    View in: PubMed
    Score: 0.072
  25. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens (Greenwich). 2008 May; 10(5):398-405.
    View in: PubMed
    Score: 0.068
  26. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.067
  27. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med. 2008 Mar 04; 148(5):400-1.
    View in: PubMed
    Score: 0.067
  28. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):27-32.
    View in: PubMed
    Score: 0.066
  29. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
    View in: PubMed
    Score: 0.066
  30. Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90.
    View in: PubMed
    Score: 0.065
  31. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26.
    View in: PubMed
    Score: 0.062
  32. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
    View in: PubMed
    Score: 0.062
  33. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7.
    View in: PubMed
    Score: 0.061
  34. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
    View in: PubMed
    Score: 0.061
  35. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol. 2006 Oct 02; 98(7A):46L-52L.
    View in: PubMed
    Score: 0.060
  36. Preventing hypertensive kidney disease: the critical role of combination therapy. Am J Hypertens. 2005 Apr; 18(4 Pt 2):93S-94S.
    View in: PubMed
    Score: 0.055
  37. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens. 2005 Apr; 18(4 Pt 2):112S-119S.
    View in: PubMed
    Score: 0.055
  38. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.054
  39. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
    View in: PubMed
    Score: 0.054
  40. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4.
    View in: PubMed
    Score: 0.052
  41. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.052
  42. Achieving blood pressure goals: is fixed-dose combination therapy the answer? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):2-3.
    View in: PubMed
    Score: 0.048
  43. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):21-8.
    View in: PubMed
    Score: 0.048
  44. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50.
    View in: PubMed
    Score: 0.048
  45. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9.
    View in: PubMed
    Score: 0.048
  46. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7.
    View in: PubMed
    Score: 0.044
  47. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001 Dec 10-24; 161(22):2661-7.
    View in: PubMed
    Score: 0.043
  48. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
    View in: PubMed
    Score: 0.043
  49. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539.
    View in: PubMed
    Score: 0.042
  50. Oral antidiabetic agents safe with renal disease? Postgrad Med. 2000 Jun; 107(7):66.
    View in: PubMed
    Score: 0.039
  51. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
    View in: PubMed
    Score: 0.037
  52. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
    View in: PubMed
    Score: 0.035
  53. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998 Oct; 11(10):158S-162S.
    View in: PubMed
    Score: 0.035
  54. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
    View in: PubMed
    Score: 0.034
  55. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
    View in: PubMed
    Score: 0.034
  56. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
    View in: PubMed
    Score: 0.034
  57. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
    View in: PubMed
    Score: 0.034
  58. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.033
  59. Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol. 1998; 31 Suppl 2:S34-40.
    View in: PubMed
    Score: 0.033
  60. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
    View in: PubMed
    Score: 0.033
  61. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11.
    View in: PubMed
    Score: 0.031
  62. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671.
    View in: PubMed
    Score: 0.031
  63. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens. 1997 Jan; 11(1):35-8.
    View in: PubMed
    Score: 0.031
  64. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996 Sep 23; 156(17):1969-78.
    View in: PubMed
    Score: 0.030
  65. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
    View in: PubMed
    Score: 0.030
  66. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
    View in: PubMed
    Score: 0.029
  67. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
    View in: PubMed
    Score: 0.029
  68. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
    View in: PubMed
    Score: 0.028
  69. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995 Oct; 10 Suppl 9:56-62.
    View in: PubMed
    Score: 0.028
  70. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54.
    View in: PubMed
    Score: 0.028
  71. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
    View in: PubMed
    Score: 0.028
  72. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21.
    View in: PubMed
    Score: 0.027
  73. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994 Jul; 46(1):161-9.
    View in: PubMed
    Score: 0.026
  74. Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'. Postgrad Med. 1994 Jun; 95(8):153-6.
    View in: PubMed
    Score: 0.026
  75. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7.
    View in: PubMed
    Score: 0.026
  76. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43.
    View in: PubMed
    Score: 0.025
  77. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22.
    View in: PubMed
    Score: 0.025
  78. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
    View in: PubMed
    Score: 0.024
  79. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8.
    View in: PubMed
    Score: 0.024
  80. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
    View in: PubMed
    Score: 0.023
  81. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8.
    View in: PubMed
    Score: 0.023
  82. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92.
    View in: PubMed
    Score: 0.022
  83. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.022
  84. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Press. 2012 Apr; 21(2):82-7.
    View in: PubMed
    Score: 0.021
  85. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.021
  86. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.
    View in: PubMed
    Score: 0.020
  87. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010 Jul 01; 363(1):98.
    View in: PubMed
    Score: 0.020
  88. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50.
    View in: PubMed
    Score: 0.019
  89. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.
    View in: PubMed
    Score: 0.019
  90. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28.
    View in: PubMed
    Score: 0.018
  91. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36.
    View in: PubMed
    Score: 0.017
  92. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
    View in: PubMed
    Score: 0.017
  93. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
    View in: PubMed
    Score: 0.016
  94. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
    View in: PubMed
    Score: 0.016
  95. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64.
    View in: PubMed
    Score: 0.016
  96. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9.
    View in: PubMed
    Score: 0.015
  97. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2):80-6.
    View in: PubMed
    Score: 0.015
  98. The cardiometabolic syndrome and calcium channel blocker combination drugs. J Cardiometab Syndr. 2007; 2(3):207-12.
    View in: PubMed
    Score: 0.015
  99. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4.
    View in: PubMed
    Score: 0.015
  100. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
    View in: PubMed
    Score: 0.015
  101. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
    View in: PubMed
    Score: 0.015
  102. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2.
    View in: PubMed
    Score: 0.015
  103. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 Jun; 18(6):797-804.
    View in: PubMed
    Score: 0.014
  104. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
    View in: PubMed
    Score: 0.013
  105. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
    View in: PubMed
    Score: 0.012
  106. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.012
  107. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
    View in: PubMed
    Score: 0.012
  108. Lithium prophylaxis and the kidney. J Affect Disord. 1981 Mar; 3(1):37-42.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.